Glaxo Report issue

Contributed to NME For profit Phase 3
Founded: Bunnythorpe New Zealand (1873)
Status: Acquired by Glaxo Wellcome (1995) → now GlaxoSmithKline (2000)

Organization Overview

First Clinical Trial
None
First Marketed Drug
1984
ranitidine (zantac)
First NDA Approval
1984
ranitidine (zantac)
Last Known Activity
1994

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Marketed Drugs (4)

clobetasol (dermovate) (1985 NDA)

ranitidine (zantac) (1984 NDA)

salmeterol (serevent) (1994 NDA)

sumatriptan (zecuity) (NDA)

Drugs in Phase 3 Trials (4)

Key: Glaxo (0) Acquired (4)

darbepoetin alfa (aranesp) (2 trials)

epoetin (Epogen) (4 trials)

methoxy polyethylene glycol-epoetin beta (Mircera) (1 trial)

peginesatide (Omontys) (17 trials)

Overview

  • Highest Phase: None
  • # of Trials: 17
  • # of Trial APIs: 4